{"id":55075,"date":"2023-03-22T12:07:49","date_gmt":"2023-03-22T11:07:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cdc-warns-deadly-drug-resistant-candida-auris-spreading-rapidly-across-us\/"},"modified":"2023-03-22T12:07:49","modified_gmt":"2023-03-22T11:07:49","slug":"cdc-warns-deadly-drug-resistant-candida-auris-spreading-rapidly-across-us","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cdc-warns-deadly-drug-resistant-candida-auris-spreading-rapidly-across-us\/","title":{"rendered":"CDC Warns Deadly Drug Resistant Candida auris Spreading Rapidly Across US"},"content":{"rendered":"
\n

\nCandida auris is a pathogenic disease commonly acquired in hospitals or long-term care facilities with no known vaccine currently available<\/b>\n<\/p>\n

\nCDC has stated that 30-60% of people with C. auris bloodstream infections die and considers it one of the most significant infectious diseases in the world today<\/b>\n<\/p>\n

MOUNT VERNON, N.Y.–(BUSINESS WIRE)–Applied UV, Inc.<\/a> (NasdaqCM: AUVI<\/a>) (\u201cApplied UV\u201d or the \u201cCompany\u201d), a leading provider of best in class suite of proprietary, patented, scientific and clinically proven, surface and air disinfection technologies (fixed, mobile and HVAC), LED lighting products and hotel furnishings used by clients globally, announces today, the Center of Disease Control (CDC) has warned that Candida auris (C. auris)<\/a> is spreading rapidly through U.S. health care facilities. As the company previously announced<\/a>, the Sterilumen family of disinfection devices was independently tested by ResInnova Laboratories (an independent microbiology testing laboratory specializing in antimicrobial technologies) who confirmed that the Company\u2019s devices kill C.auris on sink handles, achieving a log2 kill in just fifteen minutes of operation. Applied UV\u2019s recently acquired Puro UV completed independent lab testing<\/a> commissioned by Violet Defense<\/a>\u2122, the UV technology provider powering Puro\u2019s Helo products, and performed at an EPA and FDA GLP-compliant, ISO 17025 Accredited Testing Laboratory. Testing determined that Puro UV disinfecting fixtures are effective at killing the C. auris<\/i> fungus.\n<\/p>\n

\nSterilumen\u2019s complete family of air and surface disinfection devices including Airocide\u00ae Air Purification System, a proprietary airborne pathogen killing technology originally developed for use by NASA and listed as a FDA Class II Medical Device that uses a patented combination of UVC and a proprietary, titanium dioxide based photocatalyst, kills the emerging multi-drug resistant fungus, Candida auris (\u201cC. auris\u201d) as well as its surface disinfection platform Lumicide. Additionally, independent research previously conducted demonstrated that Airocide\u00ae also kills MRSA (methicillin-resistant Staphylococcus aureus).\n<\/p>\n

\nApplied UV\u2018s patented LumiCide Surface and Drain UVC Disinfecting Systems<\/a> is currently installed within the world renowned Mt. Sinai Medical Center Morningside in a trial, the results of which are expected to be published late in Q3 2023 which would further validate the previously obtained independent results conducted by ResInnova Laboratories. This validation could facilitate the adoption of the Company\u2019s LumiCide Surface and Drain disinfection solutions throughout healthcare facilities globally. Mount Sinai Morningside<\/a>, formerly known as Mount Sinai St. Luke’s, is a teaching hospital located in the Morningside Heights neighborhood of Manhattan in New York City. Mount Sinai Morningside is affiliated with the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, a nonprofit hospital system formed by the merger of Continuum Health Partners and the Mount Sinai Medical Center in September 2013. It provides general medical and surgical facilities, ambulatory care, and a Level 2 Trauma Center, verified by the American College of Surgeons. It operates 21 clinics and as of 2020, is nationally ranked by U.S. News & World Report<\/a>.\n<\/p>\n

\nCandida auris is an emerging fungal pathogen that presents a serious global health threat. It enters the body through the skin and infects the bloodstream, central nervous system, and multiple internal organs. It has been identified as being multiple drug resistant, and the disease is particularly pernicious in patients with weakened immune systems, which is why it is so problematic in hospitals and long-term care facilities. CDC currently considers Candidiasis as one of the most significant infectious diseases in the world today.\n<\/p>\n

\nApplied UV\u2019s LumiCide Disinfection System product line has the following attributes:\n<\/p>\n